Upgrade to SI Premium - Free Trial

Axsome Therapeutics (AXSM)

241.41 +9.93 (4.29%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/10/26)

Latest Headlines

Morgan Stanley tracks prescription trends for US neurology drugs June 5, 2026 8:59 AM - StreetInsider Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting June 4, 2026 7:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM) June 4, 2026 6:40 AM - StreetInsider Form 8-K Axsome Therapeutics, For: Jun 03 June 3, 2026 9:04 AM - SEC Filing Axsome settles SUNOSI patent litigation, allows generics starting 2040 June 3, 2026 7:04 AM - StreetInsider Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation June 3, 2026 7:00 AM - StreetInsider Form 4 Axsome Therapeutics, For: May 29 Filed by: Coleman Mark June 2, 2026 7:00 PM - SEC Filing Form 144 Axsome Therapeutics, Filed by: Coleman Mark June 2, 2026 4:10 PM - SEC Filing Form 144 Axsome Therapeutics, Filed by: Coleman Mark June 1, 2026 4:06 PM - SEC Filing Axsome partners with Headache Alliance for migraine awareness month June 1, 2026 7:03 AM - StreetInsider Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month June 1, 2026 7:00 AM - StreetInsider Form 144 Axsome Therapeutics, Filed by: Coleman Mark May 29, 2026 4:09 PM - SEC Filing Axsome Therapeutics to Participate in Upcoming Investor Conferences May 27, 2026 7:00 AM - Globe NewsWire Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting May 26, 2026 7:00 AM - StreetInsider Axsome Therapeutics Recognizes Mental Health Month May 7, 2026 7:01 AM - Globe NewsWire Form 4 Axsome Therapeutics, For: May 04 Filed by: Jacobson Mark L. May 5, 2026 8:35 PM - SEC Filing Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L. May 5, 2026 5:55 PM - SEC Filing Form 144/A Axsome Therapeutics, Filed by: Jacobson Mark L. May 5, 2026 5:54 PM - SEC Filing Axsome Therapeutics (AXSM) PT Raised to $255 at Wells Fargo May 5, 2026 8:55 AM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $242 at Morgan Stanley May 5, 2026 8:00 AM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $267 at Needham May 5, 2026 7:28 AM - StreetInsider Axsome Therapeutics to Participate in Upcoming Investor Conferences May 5, 2026 7:00 AM - Globe NewsWire Axsome Therapeutics (AXSM) PT Raised to Street High $310 at Mizuho, Top Pick May 5, 2026 6:05 AM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $300 at B.Riley May 5, 2026 4:20 AM - StreetInsider Form 144 Axsome Therapeutics, Filed by: Jacobson Mark L. May 4, 2026 5:43 PM - SEC Filing Form 10-Q Axsome Therapeutics, For: Mar 31 May 4, 2026 5:05 PM - SEC Filing Axsome Therapeutics (AXSM) PT Raised to $246 at Baird May 4, 2026 4:17 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $302 at RBC Capital May 4, 2026 4:07 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $280 at Oppenheimer May 4, 2026 3:19 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $260 at Guggenheim May 4, 2026 1:15 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $258 at Piper Sandler May 4, 2026 12:23 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $275 at TD Cowen May 4, 2026 12:06 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $270 at H.C. Wainwright May 4, 2026 7:28 AM - StreetInsider Form 8-K Axsome Therapeutics, For: May 04 May 4, 2026 7:08 AM - SEC Filing Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c May 4, 2026 7:01 AM - StreetInsider Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update May 4, 2026 7:00 AM - Globe NewsWire Axsome Therapeutics (AXSM) PT Raised to $255 at TD Cowen May 1, 2026 11:25 AM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $241 at Baird May 1, 2026 8:20 AM - StreetInsider Axsome AUVELITY wins FDA approval for Alzheimer's agitation treatment May 1, 2026 7:15 AM - StreetInsider Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader May 1, 2026 7:15 AM - Globe NewsWire Form 8-K Axsome Therapeutics, For: Apr 30 April 30, 2026 5:19 PM - SEC Filing Axsome Therapeutics (AXSM) PT Raised to $250 at Oppenheimer April 30, 2026 5:15 PM - StreetInsider Axsome Therapeutics (AXSM) PT Raised to $217 at Morgan Stanley April 30, 2026 3:23 PM - StreetInsider Axsome receives FDA approval for AUVELITY to treat Alzheimer's agitation April 30, 2026 2:06 PM - StreetInsider Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease April 30, 2026 2:06 PM - Globe NewsWire Axsome Therapeutics (AXSM) Halted, News Pending April 30, 2026 2:05 PM - StreetInsider Axsome Therapeutics (AXSM) PT Lowered to $228 at Mizuho April 28, 2026 9:13 AM - StreetInsider Form ARS Axsome Therapeutics, For: Dec 31 April 24, 2026 5:03 PM - SEC Filing Form DEFA14A Axsome Therapeutics, April 24, 2026 5:03 PM - SEC Filing Form DEF 14A Axsome Therapeutics, For: Apr 24 April 24, 2026 5:02 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 21 Filed by: Jacobson Mark L. April 23, 2026 9:03 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 21 Filed by: TABUTEAU HERRIOT April 23, 2026 9:02 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 22 Filed by: Maizel Ari April 23, 2026 9:02 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 21 Filed by: Maizel Ari April 23, 2026 9:01 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 21 Filed by: Pizzie Nick April 23, 2026 9:01 PM - SEC Filing Form 4 Axsome Therapeutics, For: Apr 21 Filed by: Murdock Hunter R. April 23, 2026 9:00 PM - SEC Filing Form 144 Axsome Therapeutics, Filed by: Maizel Ari April 22, 2026 4:04 PM - SEC Filing Axsome Therapeutics (AXSM) PT Raised to $259 at UBS April 10, 2026 6:05 AM - StreetInsider Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 April 8, 2026 7:00 AM - Globe NewsWire Axsome Therapeutics (AXSM) PT Lowered to $221 at RBC Capital April 7, 2026 9:05 AM - StreetInsider Piper Sandler on Axsome Therapeutics (AXSM): 'A High-Risk, High-Reward Opportunity' April 2, 2026 8:28 AM - StreetInsider Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline April 1, 2026 5:41 PM - StreetInsider Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline' April 1, 2026 12:10 PM - StreetInsider William Blair Shuffles Analyst Conviction List for April 2026 April 1, 2026 7:15 AM - StreetInsider Form 8-K Axsome Therapeutics, For: Apr 01 April 1, 2026 7:05 AM - SEC Filing Axsome acquires balipodect for schizophrenia treatment development April 1, 2026 7:00 AM - StreetInsider Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions April 1, 2026 7:00 AM - StreetInsider Mizuho stays Outperform rated on Axsome Therapeutics (AXSM) amid scripts decline March 27, 2026 8:47 AM - StreetInsider Form SCHEDULE 13G/A Axsome Therapeutics, Filed by: VANGUARD GROUP INC March 26, 2026 4:13 PM - SEC Filing Axsome Therapeutics (AXSM) PT Raised to $245 at Guggenheim March 25, 2026 6:07 AM - StreetInsider Mizuho stays Outperform on Axsome Therapeutics (AXSM) as Auvelity Rx growth accelerates March 20, 2026 11:06 AM - StreetInsider RBC Capital Defending on Axsome Therapeutics (AXSM) March 13, 2026 6:02 AM - StreetInsider Full Article List